Application note: Monitoring Aggregation of Antibody-Drug Conjugates
Posted: 30 July 2019 | Enzo Life Sciences | No comments yet
Prediction of Aggregation Propensity and Monitoring of Aggregation of Antibody-Drug Conjugates (ADC).
Innate Pharma has developed an antibody-drug conjugate (ADC) coupling technology. To validate the technology concept for clinical applications, the stability of unglycosylated SGN30 Q and S mutants coupled to the MMAE toxin by either one-step (SGN30 Q/S-linker-vcMMAE) or two-step technology (SGN30 Q/S-Linker-Click-Linker-vcMMAE) was compared to the first FDA-approved ADC, ADCETRIS® and evaluated. Utilizing the ProteoStat® Thermal Shift Assay, the temperatures of aggregation were determined and used to establish an aggregation propensity prediction ladder.
Related content from this organisation
Assays, Drug Discovery Processes, Screening, Targets
Enzo Life Sciences